EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Plasma Matrix Metalloproteinase Concentrations and Risk of Interstitial Lung Disease in a Prospective Rheumatoid Arthritis Cohort

Brent A Luedders iD, Austin M Wheeler iD, Dana P Ascherman iD, Joshua F Baker, Michael J Duryee, Yangyuna Yang, Punyasha Roul, Katherine D Wysham iD, Paul Monach iD, Andreas Reimold, Gail S Kerr, Gary Kunkel und 5 weitere

Arthritis & Rheumatology · 2024

DOI: 10.1002/art.42812 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Arthritis & Rheumatology, 2024. Verfasst von Brent A Luedders und 16 weiteren Autor:innen. Beteiligte Einrichtung: VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Arthritis, Rheumatoid, Matrix Metalloproteinase 7. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: U.S. Department of Defense, CSRD VA, VA Biomedical Laboratory Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the associations of plasma matrix metalloproteinases (MMPs) with prevalent and incident interstitial lung disease (ILD) in people with rheumatoid arthritis (RA).

Methods

Within a multicenter, prospective cohort of US veterans with RA, we performed a cross‐sectional study of prevalent ILD and cohort study of incident ILD. ILD diagnoses were validated by medical record review of provider diagnoses and chest imaging and/or pathology reports. MMP‐1, 3, 7, and 9 concentrations were measured in plasma samples, then standardized and categorized into quartiles. The associations of MMPs with prevalent and incident ILD were assessed with logistic (prevalent) and Cox (incident) regression models adjusted for RA‐ILD risk factors.

Results

Among 2,312 participants (88.9% male; mean age 63.8 years), 96 had prevalent ILD. Incident ILD developed in 130 participants over 17,378 person‐years of follow‐up (crude incidence rate 7.5/1,000 person‐years). Participants with the highest quartile of MMP‐7 concentrations had a nearly four‐fold increased odds of prevalent ILD (adjusted odds ratio 3.78 [95% confidence interval (95% CI) 1.86–7.65]) and over two‐fold increased risk of incident ILD (adjusted hazard ratio 2.33 [95% CI 1.35–4.02]). Higher MMP‐9 concentrations were also associated with prevalent and incident ILD, as well as negatively correlated with forced vital capacity among those with prevalent ILD ( r = −0.30, P = 0.005).

Conclusion

MMP‐7 and MMP‐9 were strongly associated with both prevalent and incident ILD in this large, multicenter RA cohort after adjustment for other RA‐ILD risk factors. These population‐level findings further support a potential pathogenic role for MMPs in RA‐ILD and suggest that their measurement could facilitate RA‐ILD risk stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung Diseases, InterstitialArthritis, RheumatoidMatrix Metalloproteinase 7HumansMaleMiddle AgedFemaleProspective StudiesAgedCross-Sectional StudiesIncidenceRisk FactorsMatrix Metalloproteinase 1Matrix Metalloproteinase 9Matrix Metalloproteinase 3PrevalenceCohort StudiesMatrix MetalloproteinasesUnited StatesProportional Hazards Models

Substanzen

Matrix Metalloproteinase 7MMP7 protein, humanMatrix Metalloproteinase 1Matrix Metalloproteinase 9Matrix Metalloproteinase 3MMP3 protein, humanMMP1 protein, humanMMP9 protein, humanMatrix Metalloproteinases

Autor:innen und Institutionen

  • VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha.
  • Pittsburgh VA and University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Corporal Michael J. Crescenz VA Medical Center and University of Pennsylvania, Philadelphia.
  • VA Puget Sound Health Care System and University of Washington, Seattle.
  • Boston VA, Boston, Massachusetts.
  • Dallas VA and University of Texas Southwestern, Dallas.

ORCID-Profile: Brent A Luedders, Austin M Wheeler, Dana P Ascherman, Katherine D Wysham, Paul Monach, Grant W Cannon, Jill A Poole, Ted R Mikuls, Bryant R England

Förderung

  • U.S. Department of Defense
  • CSRD VA
  • VA Biomedical Laboratory Research and Development
  • Horizon Therapeutics
  • Veterans Affairs Clinical Science Research and Development (VA CSR&D)
  • NIGMS NIH HHS
  • BLRD VA
  • VA Rehabilitation Research & Development

Zitieren

APA

Luedders, B. A., Wheeler, A. M., Ascherman, D. P., Baker, J. F., Duryee, M. J., Yang, Y., Roul, P., Wysham, K. D., Monach, P., Reimold, A., Kerr, G. S., Kunkel, G., Cannon, G. W., Poole, J. A., Thiele, G. M., Mikuls, T. R., & England, B. R. (2024). Plasma Matrix Metalloproteinase Concentrations and Risk of Interstitial Lung Disease in a Prospective Rheumatoid Arthritis Cohort. Arthritis & Rheumatology. https://doi.org/10.1002/art.42812

Vancouver

Luedders BA, Wheeler AM, Ascherman DP, Baker JF, Duryee MJ, Yang Y, et al. Plasma Matrix Metalloproteinase Concentrations and Risk of Interstitial Lung Disease in a Prospective Rheumatoid Arthritis Cohort. Arthritis & Rheumatology. 2024. doi:10.1002/art.42812

BibTeX
@article{Luedders2024,
  author = {Luedders, Brent A and Wheeler, Austin M and Ascherman, Dana P and Baker, Joshua F and Duryee, Michael J and Yang, Yangyuna and Roul, Punyasha and Wysham, Katherine D and Monach, Paul and Reimold, Andreas and Kerr, Gail S and Kunkel, Gary and Cannon, Grant W and Poole, Jill A and Thiele, Geoffrey M and Mikuls, Ted R and England, Bryant R},
  title = {Plasma Matrix Metalloproteinase Concentrations and Risk of Interstitial Lung Disease in a Prospective Rheumatoid Arthritis Cohort},
  journal = {Arthritis & Rheumatology},
  year = {2024},
  doi = {10.1002/art.42812}
}
Kostenlos starten →